行情

SBPH

SBPH

Spring Bk Pharms
NASDAQ

实时行情|Nasdaq Last Sale

2.820
-0.010
-0.35%
休市 16:00 10/18 EDT
开盘
2.820
昨收
2.830
最高
2.970
最低
2.750
成交量
2.23万
成交额
--
52周最高
14.82
52周最低
2.780
市值
4,641.48万
市盈率(TTM)
-1.8622
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SBPH 新闻

  • 丰业银行:美元自1月以来的最长跌势可能持续更久
  • 新浪财经综合.1小时前
  • 为应对脱欧协议投票 巴克莱本周日安排交易员值夜班
  • 新浪财经综合.1小时前
  • 美国对欧盟输美产品加征关税 餐饮业人士:做法很愚蠢
  • 央视.1小时前
  • 德拉吉敦促政府采取财政措施 维持贸易开放提振经济
  • 新浪财经综合.1小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

SBPH 简况

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases. The Company's SB 9200 selectively activates within infected cells the cellular proteins retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company is also developing a second SMNH product candidate, SB 11285, as an immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes (STING) pathway. The Company focuses on developing SB 9200 for the treatment of chronic hepatitis B virus (HBV).
展开

Webull提供Spring Bank Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。